United Therapeutics Corporation
United Therapeutics Extends Credit Agreement Maturity Date by One Year
Summary
United Therapeutics Corporation has extended the maturity date of its Credit Agreement by one year to March 31, 2029, as part of a routine extension under the agreement's terms. This extension pertains to an unsecured revolving credit facility of up to $1.2 billion and a second unsecured revolving credit facility of up to $800 million, both managed by Wells Fargo Bank, National Association. The move was executed pursuant to Section 2.7 of the Credit Agreement, aligning with the company's financial management strategy.
Profitelligence Alerts
Get alerts for UTHR
Be first to know when United Therapeutics Corporation files with the SEC.
Filing Categories
Advertisement
About United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company engaged in the development and commercialization of innovative pharmaceutical products. Primarily focusing on therapies to address unmet medical needs for chronic and life-threatening conditions, United Therapeutics is notable for its contributions in the field of pulmonary arterial hypertension (PAH). The company offers a portfolio of products that include both oral and inhaled treatments, such as Remodulin and Tyvaso, providing critical care solutions that significantly improve patients' quality of life. Additionally, they are investing in innovative technologies such as organ manufacturing and regenerative medicine, showcasing a commitment to future medical advances. Headquartered in Silver Spring, Maryland, United Therapeutics operates across various stages of drug research, from clinical trials to post-market analysis. As a key player in the biotechnology industry, the company holds an influential position, contributing to significant advancements in therapeutic solutions and reinforcing its role in the healthcare market by addressing complex medical challenges and patient needs effectively.
Official SEC Documents
Advertisement